[Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
We retrospectively investigated amrubicin hydrochloride(AMR)monotherapy as second or thirdline chemotherapy for small-cell lung cancer(SCLC)and assessed its efficacy and safety. AMR was intravenously administered at 25-45mg/m2 for 3 consecutive days every 3-4 weeks. Fifty-three patients were enrolled. Response rates and median survival times were as follows: total cases, 32% and 7. 4 months; sensitive relapse cases, 64% and 16. 4 months; refractory relapse cases, 27% and 5. 9 months. Neutropenia was major toxicity(Grade 3 or 4 was observed in 72% of the subjects), whereas nonhematologic toxicities were mild. Treatment with AMR appeared effective in SCLC patients previously treated with chemotherapy. On the other hand, it must be used carefully because of its relatively severe hematologic toxicities.
Nitta
Tomoko
T
Department of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital.
Yamasaki
Masahiro
M
Kajihara
Toshiki
T
Mito
Akiko
A
Awaya
Hirokazu
H
Ikegami
Yasuhiko
Y
Arita
Kenichi
K
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D018943:Anthracyclines / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
D018943:Anthracyclines; D000970:Antineoplastic Agents; C055866:amrubicin